메뉴 건너뛰기
Journal of Oncology Pharmacy Practice
Volumn 23, Issue 8, 2017, Pages 638-640
Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer
Author keywords

curly hair; lung cancer; nivolumab; PD 1 PD L1 inhibitor
Indexed keywords

CARBOPLATIN; NIVOLUMAB; PACLITAXEL; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;
EID: 85032292636     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155216674355     Document Type: Article
Times cited : (18)
References (8)
  • 1
    • 0019799332 scopus 로고
    • A method for estimating the probability of adverse drug reactions
    • Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
    • (1981) Clin Pharmacol Ther , vol.30 , pp. 239-245
    • Naranjo, C.A.1    Busto, U.2    Sellers, E.M.3
  • 2
    • 84922516101 scopus 로고    scopus 로고
    • Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane
    • Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 2015; 72: 203-218.
    • (2015) J Am Acad Dermatol , vol.72 , pp. 203-218
    • MacDonald, J.B.1    MacDonald, B.2    Golitz, L.E.3
  • 3
    • 84941111889 scopus 로고    scopus 로고
    • Management of dermatologic complications of lung cancer therapies
    • Pugliese SB, Neal JW, Kwong BY,. Management of dermatologic complications of lung cancer therapies. Curr Treat Options Oncol 2015; 16: 50-50.
    • (2015) Curr Treat Options Oncol , vol.16 , pp. 50
    • Pugliese, S.B.1    Neal, J.W.2    Kwong, B.Y.3
  • 4
    • 84876576654 scopus 로고    scopus 로고
    • Pigmentary disorders induced by anticancer agents. Part II: Targeted therapies
    • Sibaud V, Robert C,. Pigmentary disorders induced by anticancer agents. Part II: targeted therapies. Ann Dermatol Venereol 2013; 140: 266-273.
    • (2013) Ann Dermatol Venereol , vol.140 , pp. 266-273
    • Sibaud, V.1    Robert, C.2
  • 5
    • 84906538234 scopus 로고    scopus 로고
    • Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab
    • Choi JN,. Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab. Semin Cutan Med Surg 2014; 33: 40-48.
    • (2014) Semin Cutan Med Surg , vol.33 , pp. 40-48
    • Choi, J.N.1
  • 6
    • 84875887098 scopus 로고    scopus 로고
    • Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: Two illustrative cases
    • Assi H, Wilson KS,. Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases. Curr Oncol 2013; 20: e165-e169.
    • (2013) Curr Oncol , vol.20 , pp. e165-e169
    • Assi, H.1    Wilson, K.S.2
  • 7
    • 65249186765 scopus 로고    scopus 로고
    • Persistent hair growth during treatment with the EGFR inhibitor erlotinib
    • Alexandrescu DT, Kauffman CL, Dasanu CA,. Persistent hair growth during treatment with the EGFR inhibitor erlotinib. Dermatol Online J 2009; 15: 4-4.
    • (2009) Dermatol Online J , vol.15 , pp. 4
    • Alexandrescu, D.T.1    Kauffman, C.L.2    Dasanu, C.A.3
  • 8
    • 85044145286 scopus 로고    scopus 로고
    • Late-onset robust curly hair growth in a patient with BRAF-mutated metastatic melanoma responding to dabrafenib
    • Epub ahead of print 4 March
    • Keating M and Dasanu CA. Late-onset robust curly hair growth in a patient with BRAF-mutated metastatic melanoma responding to dabrafenib. J Oncol Pharm Pract. Epub ahead of print 4 March 2016. pii: 1078155216635854.
    • (2016) J Oncol Pharm Pract.
    • Keating, M.1    Dasanu, C.A.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.